BioMerieux (STU:EYWN) Dividends Received


STU:EYWN BioMerieux SA STU:EYWN
65 GF Score
Price €69.60
GF Value €109.74
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioMerieux Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:EYWN
65GF Score
BioMerieux SA STU:EYWN
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioMerieux (STU:EYWN) Overvalued in 2026?

Based on GuruFocus' analysis, BioMerieux stock appears to be undervalued. The current stock price of €69.60 is trading 36.6% below its estimated GF Value™ of €109.74. GuruFocus considers BioMerieux to be Significantly Undervalued.

Key valuation signals for STU:EYWN:

  • Dividends Received:
  • GF Value™: €109.74 vs. price of €69.60 (36.6% below fair value)
  • GF Score™: 65/100 with 3 warning signs

No single metric tells the full story. See the STU:EYWN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioMerieux Business Description

Address Marcy l’Etoile, Lyon, FRA, 69280
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.
65GF Score

Get the complete analysis for STU:EYWN

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€69.60
Price
€109.74
GF Value